Cytokinetics, Incorporated — Income Charts
2 years of history · ending 2025-12-31 · SEC EDGAR
Source:10-K · 10-Q
Revenue, Gross Profit, Operating Income & Net Income
Margin (%)
Operating Expenses
Income Breakdown
Revenue
$88M
R&D
$416M
D&A
$10M
Operating Income
$-612M
EBITDA
$-602M
Interest Expense
$46M
Interest Income
—
Other Income/Expense
—
Pretax Income
—
Tax Provision
$0
Net Income
$-785M
Operating Margin
-695.4%
Net Margin
-891.6%
Effective Tax Rate
—
Deferred Tax Assets
—
Deferred Tax Liabilities
$5M
DTA Valuation Allowance
$859M
Tax Credit Carryforwards
$168M
NOL Carryforwards
$499M
ETR (Continuing Operations)
0.0%
ETR Federal Statutory
21.0%
ETR State + Local (pp)
0.0%
ETR Foreign Differential (pp)
0.0%
Operating Lease Cost
—
Revenue YoY Variation
376.6%
Income YoY Variation
-14.2%